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INTRODUCTION 
Diabetes Mellitus (DM) is an important health issue today. 
According to World Health Organization (WHO), the number of people 
with diabetes has increased from 177 million in 2010 to 326.5 million in 
2017,in the age group of 20-64 years. It is expected that the number will 
be around 438 million by the year 2040.In 2017 alone is considered, 
China is the country with highest number of people with diabetes, with 
114 million people suffering from DM. Next to China, India has the next 
highest number. India contributes 49% of the world’s diabetes burden, 
with around 72 million in 2017 .The data show that the number is 
expected to increase to 134 million by 2025. 
Diabetic retinopathy is one of the leading causes of blindness in the 
world in the age group of 20 to 75 years. Diabetic retinopathy is seen to 
be affecting 75% of those with diabetes and tends to develop diabetic 
retinopathy after a mean duration of 15 years.1 Blindness in diabetic 
retinopathy is due to tractional detachment of retina, long standing non 
clearing vitreous hemorrhage and due to diabetic macular edema. 
Macular edema is the leading cause of visual loss in diabetic retinopathy 
patients .Clinically significant macular edema (CSME) is seen in upto 4% 
of the people with diabetes.1 
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Increase in the severity of retinopathy leads to an increase in the 
incidence of macular edema. It is seen in non-proliferative as well as 
proliferative diabetic retinopathy. 
The term diabetic maculopathy is applied to a range of pre retinal 
and intra retinal changes occurring at the macula. Retinal ischemia due to 
capillary and arteriolar non perfusion and breakdown of blood-retinal 
barrier are the major changes occurring intra retinally in diabetic 
retinopathy. Diabetic macular edema can develop in any stage of 
retinopathy and is seen to produce both the structural and functional 
changes at the macula. 
The two major categories of macular edema in diabetic 
maculopathy are focal macular edema and diffuse macular edema. 
1. Focal macular edema is characterized by focal leakage of  micro 
aneurysms, dilated capillary segments and is often seen with hard 
exudates ring formation. 
2. Diffuse macular edema is characterized by widespread retinal 
capillary abnormalities and is due to diffuse leakage following 
extensive breakdown of blood retinal barrier. It affects the entire  
posterior pole and often leads to cystoid macular edema. 
 
 
3 
 
Effects of diabetes on macula: 
1) Pre retinal or intra retinal hemorrhage. 
2) Macular edema- collection of fluid within the layers of retina in the 
macula with or without hard exudates and cystoid changes. 
3) Traction at macula: It is caused by proliferation of fibrous tissue 
causing tangential traction or wrinkling of retina or detachment of 
retina at macula. 
4) Lamellar or full thickness macular hole formation. 
The ETDRS has defined Clinically Significant Macular Edema 
(CSME) as macular edema that meets certain criteria for location and 
size. In case of presence any one of the following criteria, CSME is said 
to be present: 
i. Retinal thickening  within 500µm of the center of the macula 
ii. Exudates within 500µm of macula ,if associated with retinal 
thickening. The thickening may be outside the 500µm. 
iii. Retinal thickening of one disc area(1500µm) or larger, any part of 
which is within one disc diameter of the center of macula.2 
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DME is divided into Centre involving (500µm) and Non center 
involving (outside 500µm),based on the criteria of involvement of  fovea 
in Optical Coherence Tomography(OCT)2 
Those patients with edema at the macula develop dimension of 
vision and those people whose macula is spared have an excellent visual 
acuity. Once DME develops, it is difficult to bring back the full vision 
and treatment is mainly aimed to stabilise the pretreatment vision and 
also vision improvement occur in few cases. Thus it is of prime 
importance to examine diabetic patients regularly before the vision drops, 
so that timely intervention can be done before the condition becomes 
beyond the scope of treatment. 
There are particular retinal lesions identified on FFA has to be treated. 
These ‘treatable lesions’ associated with macular edema include- 
1) Focal leaks > 500 µm from center of macula believed to be causing 
retinal thickening or hard exudates. 
2) Focal leaks 300–500 µm from the center of macula believed to be 
causing retinal thickening or hard exudates, if there is surety that 
the remaining peri foveal capillary network will not be destroyed 
3) Previously untreated areas of diffuse leakage. 
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4) Previously untreated avascular zones, other than ‘FAZ’ . 
 In the ETDRS, 2 types of photo coagulation methods were used for 
treatment of diabetic macular edema namely focal and grid. 
Focal refers to direct treatment of all leaking micro aneurysms in the 
edematous retina, between 500-3000µm from the center of macula. 
Grid treatment is used primarily for identifiable diffuse leakage 
areas and thickened retina. 
Elevated lipid levels are associated with endothelial dysfunction, 
which appears to play an important role in the pathogenesis of DR, 
particularly in relation to break down of blood retinal barrier and 
development of CSME and hard exudates. Patients with diabetes are 
known to have severe lipid abnormalities like hyper cholesterolemia and 
elevated serum triglycerides. The WESDR, a population based study and 
the ETDRS found that increased levels of serum cholesterol were 
associated with increased severity of hard exudates in retina. Independent 
of accompanying macular edema, the severity of retinal hard exudates at 
base line was associated with decreased visual acuity in the ETDRS. The 
severity of retinal hard exudates also was a significant risk factor for 
moderate vision loss during the course of the study. The data are 
compelling to recommend lowering raised serum lipid levels in patients 
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with DR to reduce the risk of visual loss besides reducing the risk of 
cardiovascular disease. The current study done to assess the correlation of 
levels of serum lipids with the development of Clinically significant 
macular edema in our population.   
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AN OVERVIEW OF DIABETES MELLITUS 
Diabetes mellitus is classified by the American Diabetic 
Association  into type 1 diabetes mellitus or IDDM( insulin-dependent 
diabetes mellitus) and type 2 diabetes mellitus or NIDDM (non– insulin-
dependent diabetes mellitus. In type 1 DM, there is β-cell destruction, 
leading to absolute deficiency of insulin. It is either idiopathic or immune 
mediated. T2DM can be either insulin resistance with relative insulin 
deficiency or defect of insulin secretion with insulin resistance. Other 
forms include genetically mediated, secondary to endocrinopathies and 
DM following usage of drugs and induced by chemicals.2  Type 2 DM 
consists of 90% and is predominant in 4th decade.Type2 DM in children 
and adolescents in on the rise.Type 1 DM is more associated with 
diabetic retinopathy.3In those presenting to clinicians it is seen to be more 
associated with type2 as the number of people with type2 is more.2 
Chronic effects of DM includes nephropathy, neuropathy and 
retinopathy affecting the microvascular circulation of kidney, peripheral 
nerves and retina. Eventhough the changes in the metabolism affect the 
neurons and the support cells directly, it is the changes occurring in the 
vessels which leads on to the development of macular edema and new 
vessel formation.1 
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CLASSIFICATION OF DIABETIC RETINOPATHY 
The ETDRS (Early Treatment Diabetic Retinopathy Study) has 
classified Diabetic Retinopathy into NPDR(Non Proliferative Diabetic 
Retinopathy) and PDR(Proliferative Diabetic Retinopathy. This 
classification is based on the findings in the clinical examination and 
comparing it with the standard photographs. Very mild NPDR, mild 
NPDR, moderate NPDR, severe and very severe NPDR forms the further 
classification of NPDR. Mild-moderate, High risk PDR and (ADED) 
Advanced Diabetic Eye Disease forms the sub classification of 
PDR.2Chronically elevated blood glycemic levels is the most important 
factor leading to the development of diabetic retinopathy and its various 
complications.1 
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RELEVANT ANATOMY 
Various anatomic lesions associated with diabetic retinopathy 
includes: 
1) LOSS OF PERICYTES : 
It is one of the earliest and most specific signs of diabetic 
retinopathy. It was described for the  first time by Cogan et.al.4-6They had  
examined mounts containing trypsin-digested retinal vessels from 
diabetic patients. Microvascular auto regulation is maintained mainly 
with the help of these contractile pericytes. Pericyte loss leads to changes 
of vascular intercellular contacts and inner blood–retina barrier 
impairment. These leads to venous dilation and beading that is seen in 
fundus examination clinically. Microaneurysms develop due to 
proliferation of endothelial cells following loss of intercellular contacts.7 
The mechanism by which chronic hyperglycemia leads to pericyte 
degeneration remains largely unknown. The two leading hypotheses 
implicate the aldose reductase pathway and platelet-derived growth 
factor-beta (PDGF-β). 
2) CAPILLARY BASEMENT MEMBRANE THICKENING: 
Thickening of capillary basement membrane can be seen on 
electron microscopy and is lesion well associated with diabetic 
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retinopathy. Fibrillar collagen and “Swiss cheese” vacuolization of the 
basement membrane forms the other electron microscopic findings of 
DR. The biochemical mechanism leading to basement membrane 
thickening remains unknown but studies suggest a role for the aldose 
reductase and the sorbitol pathway.8,9 
3) MICROANEURYSMS: 
It is the earliest ophthalmoscopically visible sign of DR, appearing 
as tiny red intra retinal dots.10In light microscopy, it appears as grape-like 
or spindle-shaped dilations of retinal capillaries.11 They can be either 
hypercellular or acellular. Loss of the ant proliferative effect of pericytes 
leads to the formation of hypercellular microaneurysms. Endothelial cell 
and pericyte apoptosis of the hypercellular microaneurysms leads to the 
development of acellular microaneurysms.12 
4) BREAKDOWN OF BLOOD–RETINA BARRIER : 
Blood–retina barrier breakdown is a significant pathophysiologic 
change in diabetic retinopathy  leading to the development of edema, the 
leading cause of loss of vision in diabetic patients. One of the 
mechanisms of functional alteration of this barrier involves opening of 
the tight junctions known as zonula occludens that are seen between 
vascular endothelial cell processes.13,14 
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BIOCHEMICAL MECHANISMS IN THE 
PATHOGENESIS OF  DIABETIC RETINOPATHY 
1) CHRONIC HYPERGLYCEMIA: 
It is the most important causative factor leading to all the 
microvascular complications of diabetes, including diabetic retinopathy. 
Leukocyte activation followed by release of cytokines and adhesion 
molecules occurs. These molecules leads to the increased adhesion of 
leukocytes to the capillary walls leading to occlusion and hypoxia.15-17 
In the aldose reductase theory ,increase of glucose inside the cells 
leads to increased activation of the aldose reductase pathway or the 
polyol pathway.18,19The sorbitol formed from glucose through this 
pathway accumulates inside the cell producing its various effects. 
2) ADVANCED GLYCATION ENDPRODUCT  (AGE) THEORY: 
One another factor implicated in the development of complications 
in DM is the formation of AGEs or the Advanced Glycation End 
Products.20 AGEs is the collective terminology used for proteins, lipids, 
and nucleic acids which undergo irreversible modification by reducing 
sugars or sugar-derived products through a reaction called Maillard 
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reaction. It is this reaction which is responsible for the browning of 
tissues with ageing. 
3) REACTIVE OXYGEN INTERMEDIATES (ROI) THEORY:  
It is one of the oldest theories proposing  that increasing oxidative 
stress due to chronic hyperglycemia leads to complications of diabetes. 
Usually metabolism of glucose occurs via glycolytic and the tricarboxylic 
acid pathway, which produces adequate reducing equivalents for the 
production of  Adenosine Triphosphate (ATP) via the oxidative 
phosphorylation. But high levels of glucose21 leads to increased 
production of byproducts of oxidative phosphorylation, such as 
superoxide anion, also. Increased free radicals like superoxide anion leads 
to damage of mitochondrial DNA22 and also reduces the levels of nitric 
oxide 23,24,thus promoting adhesion of leukocytes to endothelium 25 and 
damage of cellular proteins.26 
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RISK FACTORS FOR DIABETIC RETINOPATHY 
1) RACE: 
Evaluation of race showed that the occurrence and the severity of 
type 1 diabetes is the same in the Africans Americans when compared to 
the whites 27,28  and that type 2 is more prevalent among African 
Americans as evidenced in the Atherosclerotic Risk in Communities 
(ARIC) study 29,the Cardiovascular Health Study 30 and the Multi Ethnic 
Study of Atherosclerosis 31.In a study conducted at Dr.Mohan’s diabetic 
specialty centre at Chennai, by Dr Rema and Dr.Pradeepa, it was found 
that the prevalence of DR as much lesser than the age matched  western 
population.32 
2) GENETIC FACTORS : 
A number of studies give more strong association of diabetic 
retinopathy and genetic factors than previously thought. 33,34 Possible 
causal factors implicated  in the pathogenesis of diabetic retinopathy were 
aldose reductase activity, oxidative stress and  platelet adhesiveness and 
aggregation, collagen formation, inflammatory process, glycation, protein 
kinase activity. Extensive study of these factors helped to conclude the 
association of these factors in the genetic predisposition of diabetes. 
There are already a number of studies that have reported associations 
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between retinopathy and mitochondrial DNA mutations and 
polymorphisms of the aldose reductase gene,35,36 TNF-beta NcoI gene,37 
epsilon4 allele of apolipoprotein E gene,38 paraoxonase gene,39 
endothelial nitric oxide synthase gene,40 intercellular adhesion molecule-1 
(ICAM-1),41 alpha2beta1 integrin gene,42 vascular endothelial growth 
factor (VEGF) gene, and many more.43,44 
3) SEX: 
On comparison of young males with females the former had higher 
prevalence of proliferative retinopathy.2 However, there were no 
significant differences in progression of diabetic retinopathy between the 
sexes.46,47,48 Among those with type 2 diabetes there were no significant 
difference in the prevalence or rates of progression to PDR between the 
sexes, in WESDR.47,49,50 
4) AGE AND PUBERTY: 
In WESDR type 1 diabetics had increased prevalence  and severity 
as the age advanced. Irrespective of the duration of diabetes, those 
younger than 13years had no evidence of diabetic retinopathy. 
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In the WESDR, after adjusting for other risk factors, it was 
observed that those who had attained menarche had three times increased 
risk for retinopathy as compared to the premenarchal. 
5) DURATION OF DIABETES : 
It is the most consistent association of diabetic retinopathy as 
understood from all the studies done related to it. Duration of diabetes is 
seen to affect the frequency, severity and the development of 
maculopathy.45 The WESDR showed a 14% prevalence in men and a 
24% prevalence among women after a 3-4 years of detection of diabetes 
in those with type1 DM.  However, in patients who has longer  duration 
of diabetic history(19-20 years),it was observed that men had more 
prevalence 50% of PDR when compared to women(33%).Those with 
type 2 developed retinopathy earlier than those with type 1. 
6) AGE AT DIAGNOSIS:  
Age at diagnosis did not show any relation to incidence or 
progression of diabetic retinopathy in any of the groups in WESDR.46,50  
7) BLOOD PRESSURE : 
Blood pressure is a significant predictor of the incidence of DR in 
patients with type1 DM, according to the WESDR.48When other risk 
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factors were adjusted, it was found that the relationship between BP and 
retinopathy remained only in the younger onset group. However, in the 
WESDR no relationship was found with the incidence and progression of 
retinopathy in type 2 DM patients.51 In contrast to it in the UKPDS it was 
observed that BP is a risk factor for the development of retinopathy. It as 
seen that the complications of DM reduced by 13% for every 10mmHg 
reduction in BP. No threshold was found for any retinopathy endpoint.52 
In the WESDR, increase in diastolic BP by 10 mmHg lead to a 330% and 
210%  increase in the  4-year risk of developing macular edema in those 
with type 1 DM and type 2 DM respectively.53 
8) SERUM LIPIDS: 
 In the WESDR, higher serum total cholesterol was associated with 
higher prevalence of retinal hard exudates which was seen in  both the 
younger and the older onset groups taking insulin. In contrast, type 2 
diabetics using oral hypoglycemic agents, did not show such 
association.54 In the ETDRS, baseline high values of serum lipids were 
observed to be associated with increased risk of developing hard exudates 
in the macula and decreased visual acuity.55  Santos et al. did a study on 
Mexican population with type 2 DM  and found that 56 the frequency of 
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severe retinal hard exudates was higher in those with the epsilon4 allele 
polymorphism of the apolipoprotein E gene. 
9) PROTEINURIA AND DM NEPHROPATHY: 
Studies concluded that those patients who had gross proteinuria or 
showed evidence of microalbuminuria on testing had more prevalence of 
retinopathy also.45,47,49,57,58,59,60,61,62,63 It was estimated that the lipid, 
platelet and the rheological abnormalities seen in case of nephropathy is 
reason for retinopathy .Chronic kidney disease people are noted to have 
higher risk of macular edema and it as seen to improve when the renal 
function recovered well. 
10) SMOKING : 
Smoking due to its effect of increased carbon monoxide in blood 
leads to tissue hypoxia  and  also because of its ability to increase the 
platelet adhesion and aggregation ,it results in increased complications of 
diabetes 64, 65 
11) ALCOHOL: 
As usage of alcohol leads to decreased glucose level, decreased 
inflammation and reduced platelet aggregation, it was expected to be 
beneficial in the prevention of development of DR. In the EURODIAB 
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Prospective Study of Complications in those with type 1 DM, regular 
alcohol usage was found to have protective effect by delaying the 
progression of retinopathy. 66There were other studies with conclusion 
contratry to the above mentioned study.67,68 A population-based study 
done in Australia, showed no association between alcohol use and 
diabetic retinopathy.69 The ADVANCE Retinopathy Measurements 
(ADREM) also showed no evidence of relation between alcohol and 
retinopathy in type 2 DM patients. In the UKPDS, men who had alcohol 
consumption history and were recently diagnosed to be diabetic, showed 
an increased severity of retinopathy.70 
12) PHYSICAL ACTIVITY: 
As proved by many studies, adequate exercises have a beneficial 
effect on glycemic control, and hence  associated with decreased 
prevalence and incidence of diabetic retinopathy.71  
13) OTHER OCULAR FACTORS:  
Becker72  reported that a decreased prevalence and severity of 
diabetic retinopathy were seen in those with glaucoma. Other studies 
have reported similar results. There were other studies also reporting 
similar results but has never been confirmed by a methodologically 
precise epidemiological study. 
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Myopia is another one factor found to be associated with lesser 
prevalence and severity of diabetic retinopathy.73 This association of 
myopia was proven in a study by Rand et al.74 who found an interesting 
interaction between myopia of greater than 2 diopters and HLA-D-group 
antigens. 
INVESTIGATIONS : 
1. Fundus Fluorescein Angiography(FFA) 
2. Fundus Auto Fluorescence(FAF) 
3. Optical Coherence Tomography(OCT) 
4. Optical Coherence Tomography Angiogram(OCTA) 
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TREATMENT OF DIABETIC MACULAR EDEMA (DME) 
DME is the most important cause of drop in visual acuity  in 
patients with diabetic retinopathy. The ETDRS has proved that in those 
with CSME laser treatment helps in the reduction of  visual loss. In the 
ETDRS, after a 3 year follow up, it was observed that CSME patients 
who received no treatment, 33% had significant visual loss. Irrespective 
of the visual acuity, patients should be given laser treatment as it helps to 
reduce the loss of vision by 50%. 
Mechanism of action of laser in DME: 
1) Focal laser helps to improve DME by stopping the leakage from 
the microaneurysms by coagulating it. 
2) Laser treatment help to maintain the integrity of the outer blood 
retinal barrier by decreasing the substances which cause mitosis 
of endothelial cells. Lesser leakage and more absorption reduce 
the DME.  
3) Laser treatment helps to reduce the oxygen consumption by  
destroying some of the photo receptors and retinal pigment 
epithelial cells which  consume most of the oxygen. Scarring 
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following treatment also leads to thinning of the retina which 
allows for better diffusion of oxygen from the choroids.  
4) Dilated and leaky retinal capillaries become narrower and less 
leaky after laser treatment. 
The techniques of laser treatments in DME are: 
1)LASER TREATMENT: 
A)Focal treatment: Involves application of laser burns to the micro 
aneurysms and micro vascular lesions in the center of rings of hard 
exudates located 500 to 3000 µm from the center of the macula. 
Spot size :50-100 µm  
Duration : 0.1 seconds 
Power: sufficient to obtain gentle whitening or darkening of the lesions.  
Treatment up to 300 µm from the center of the macula may be 
considered if CSME persists despite previous treatment and visual acuity 
is < 6/12. In these cases a shorter exposure time of 0.01 seconds is 
recommended. 
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B)Grid treatment: It is used for diffuse retinal thickening located more 
than 500 µm from the center of the macula and 500 µm  from temporal 
margin of the optic disc.  
Spot size:100 µm  
Duration: 0.1 sec 
One burn width apart. 
It takes around 4 months for the edema to resolve. Approximately 70% of 
eyes achieve stable visual acuity, 15% show improvement and 15% 
subsequently deteriorate. Re treatment may be considered after 4 months. 
3)Anti VEGFs: These act by binding to various Vascular Endothelial 
Growth Factor ( VEGF) receptors and thus inhibiting angiogenesis, 
vascular permeability and lymphangiogenesis caused by increased 
expression of the VEGF molecules. Ranibizumab is a humanized murine 
monoclonal antibody fragment, which binds to VEGF-A, Pegabtinib 
binds to VEGF-A 165 isoform. Aflibercept/ VEGF trap binds both VEGF 
and PIGF(placental like growth factor)  
4)Intra vitreal triamcinalone acetonide: may be attempted for those 
cases that fail to respond to conventional laser photocoagulation. It 
effects decreases after six months and macular edema frequently returns. 
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5) Intravitreal implants:  Intravitreal insert called Iluvein give sustained  
release of fluocinolone acetonide and was seen to produce significant 
benefit in the treatment of DME. 
Another intravitreal implant is the one containing dexamethasone 
(Ozurdex). 
5)Posterior subtenon triamcinalone acetonide: when given along with 
laser it may aid in improving vision.  
6)Pars Plana Vitrectomy: is considered when macular edema is 
associated with tangential traction. OCT aids in demonstrating eyes with 
marked vitreoretinal traction that may benefit most from surgery. 
7)Hypo lipidemic drugs have been shown to reduce the severity of hard 
exudates and sub foveal lipid migration in eyes with CSME in type 2 
diabetes mellitus patients with dyslipidemia and may become an 
important therapeutic adjunct.  
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AN OVERVIEW OF HYPERLIPIDEMIA 
Lipids are a heterogeneous group of water insoluble organic 
molecules that can be extracted from tissues by non polar solvents. Due 
to their insolubility in aqueous solutions, body lipids are generally found 
either compartmentalized or transported in association with proteins as 
lipoproteins. These particles include chylomicrons , very low density 
lipoprotein(VLDL) , low density lipoprotein(LDL) and high density 
lipoprotein(HDL). 
Triglycerides and the esterified form of cholesterol (Cholesteryl 
ester) are non-polar and hydrophobic and comprise the lipoprotein core. 
Phospholipids and some free cholesterol are amphipathic molecules 
(soluble in both aqueous and lipid envelop) which cover the surface of the 
particle, where they act as interface between plasma and core 
components. 
 Cholesterol is an important lipid which has a very low solubility in 
water. The actual plasma concentration  of cholesterol in healthy people 
is usually 150-200mg/dl. Due to the presence of plasma lipoproteins, 
cholesterol has high solubility in blood. Majority  (around 70%) of the 
cholesterol in plasma lipoproteins exist in the form of cholesterol esters 
and only 30% occurs as free in the circulation.  
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  It is the precursor of bile acids, which are synthesized in the liver 
and that facilitates the absorption of triglycerides and fat soluble 
vitamins. It is also acts as the precursor of various steroid hormones. 
HYPERLIPIDEMIAS: 
The most widely accepted classification of hyperlipidemia is that 
of Frederickson’s classification. It is divided into  
1) Type I:showing an increase of chylomicrons. Eruptive 
xanthomas and hepatomegaly is seen. 
2) Type IIA/Primary Familial Hypercholesterolemia. It is caused 
due to LDL receptor defect. It may be due to deficiency of LDL 
receptor as such or due to defective binding of B-100 to the 
receptor or due to defective internalisation of the receptor –LDL 
complex. Common cause of coronary artery disease and tuberous 
xanthoma. 
3) Type IIB/Hyperlipoprotenemia: There is increase of both 
cholesterol and triglycerides and an increased production of  
apo-B, thus leading to an elevation of LDL and VLDL. Corneal 
arcus is a manifestation of it. 
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4) Type III:It is characterised by an increase in VLDL and 
chlomicrons. It causes palmar xanthoma and also leads to a high 
incidence of vascular diseases. 
5) Type IV/Familial Endogenous Type:It is due to over production 
of TG by the liver. VLDL is seen to be elevated. It is associated 
with diabetes mellitus, ischemic heart disease and obesity.  
6) Type V: Increase in VLDL and Chylomicrons is noted. 
Ischaemic heart disease is highly associated.  
Classification of Total cholesterol, LDL Cholesterol and HDL 
Cholesterol values: 
 
Total 
Cholesterol 
Triglycerides HDL-C LDL-C 
Desirable 
<200 mg/dL <150mg/dL >60 mg/dL <130 mg/dL 
5.2 mmol/L <1.7 mmol/L >1.55mmol/L <3.36  mmol/L 
Borderline 
200-239 mg/dL 150-199mg/dL 35-60mg/dL 130-150 mg/dL 
5.5-6.18mmol/L 1.8-2.2 mmol/L 
0.9-1.55 
mmol/L 
3.36-4.14 
mmol/L 
Undesirable 
>240 mg/dL >200mg/dL <35mg/dL >160 mg/dL 
>6.21 mmol/L >2.3 mmol/L <0.9mmol/L >4.14 mmol/L 
 
  
 
 
27 
 
Treatment of dyslipidemias: 
Non Pharmacological Treatment : 
It includes dietary modification. Physician should carefully asses 
the current diet taken by the patient and suggest modification to improve 
the dyslipidemic status.  
Other factors include, cessation of smoking, decrease alcohol 
intake, weight reduction  and regular exercises. 
Pharmacological Treatment : 
1) HMG COA reductase inhibitors (statins): HMG COA reductase 
inhibits the rate limiting step in cholesterol biosynthesis and inhibitors of 
this enzyme decreased cholesterol synthesis. It not only causes dose 
dependent reduction in plasma levels of LDL & TGs but also an increase 
in HDL levels. 
Eg. Lovastatin, Provastatin, Simvastatin, Fluvastatin, Atorvastatin, 
Rosuvastatin. 
2)Cholesterol absorption inhibitors: 
Ezetimibe is a cholesterol absorption inhibitor that blocks the cholesterol 
absorption from the micelle in the intestine. It has been shown to decrease 
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cholesterol also by almost 60%. It can be used in combination with 
statins. 
3) Bile Acid sequestrants (Resins) : BAS 
It bind bile acids in the intestine and promote their excretion. To 
maintain bile acid pool size, the liver diverts cholesterol to bile acid 
synthesis. 
Eg. Cholestyramine, colestipol, colesevelam 
4) Nicotinic Acid (Niacin): 
Niacin is a lipid modifying agents which inhibit lipolysis leading to 
a decreased level of plasma TG and LDL levels and an increased HDL – 
C. It is also the only currently available lipid lowering agent that 
significantly reduces plasma levels of lipoprotein(a). 
5) Fibric acid derivatives (Fibrates): 
These decrease the levels of triacylglycerols by activating 
lipoproteinlipase and inhibiting secretion of VLDL by acting as agonists 
of PPAR alpha, a nuclear receptor involved in the regulation of 
carbohydrate and lipid metabolism. Fibrates are the most effective drugs 
available for reducing TG, VLDL and increasing HDL C. 
Eg:Gemfibrosil 
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6) Omega 3 Fatty Acids (Fish oils) 
This polyunsaturated fatty acids are present in high concentrations 
in fish and in flax seeds. Use of low dose of Omega 3 has been proved to 
decrease fasting TG levels and also cause a reduction in cardiovascular 
events in CHD patients. 
7) Probucol 
        It is believed to act at ABCA1.It acts by increasing the LDL 
catabolism and prevents accumulation of LDL in arterial walls. 
Disadvantage is that it also decreases the levels of HDL. 
8)Vit E 
          Its anti oxidant property decreases the oxidation of LDL, thus 
reducing atherosclerosis. 
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REVIEW OF LITERATURE 
Major studies related to lipid abnormalities and diabetic 
retinopathy: 
The Wisconsin Epidemiologic Study of Diabetic Retinopathy 
(WESDR) XIII 54was done to elucidate the relationship of development 
of hard exudates with serum cholesterol. Serum total cholesterol showed 
a significant association with the severity of DR and hard exudates in 
those patients taking insulin. HDL was found to be unrelated to the 
severity of lesions. 
The Early Treatment Diabetic Retinopathy Study( ETDRS) 
Report 22 55 was published in 1996,which included 2709 patients with 
DR. Results showed that those with elevated serum cholesterol or serum 
LDL had more chance of developing hard exudates in the retina. 
The United Kingdom Prospective Diabetes Study(UKPDS) 70 is 
a multi centre, randomised control study done in those with non insulin 
dependent diabetes mellitus patients. In this study it was noted that even 
HDL cholesterol levels were also associated with severity of diabetic 
retinopathy. They did not give any explanation for such an observation. 
In addition, LDL and triglycerides did not appear to be related to the DR 
severity. 
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The Diabetes Control and Complications Trial (DCCT) 76 
evaluated the relationship between serum lipid levels and Clinically 
Significant Macular Edema(CSME),hard exudates and other end points in 
DR.Study was conducted in 1441 patients with type 1 DM. It was found 
from the study that increased LDL and total cholesterol to HDL ratio 
showed an increased possibility of development of CSME and hard 
exudates. They concluded that drugs to reduce the level of lipids decrease 
the risk of CSME. 
The Multi Ethnic Study of Atherosclerosis(MESA) 31 was done 
in the multi ethnic population of US. In this study they found that 
DR,CSME or vision threatening retinopathy were not significantly 
associated with HDL,LDL and TG. 
The Chennai Urban Rural Epidemiology Study(CURES) Eye 
Study 2 77 studied 1736 patients with type 2 DM with diabetic 
retinopathy and found that average value of serum HDL,TG and 
cholesterol  were significantly higher than those without diabetic 
retinopathy. They also observed that DME was associated with non HDL 
cholesterol and LDL-C. 
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Ucgun et.al 78 from Turkey conducted a small study  to assess the 
correlation between serum lipid levels and exudative maculopathy in 
diabetic patients with non-proliferative retinopathy. Fifty patients were 
equally divide into those with maculopathy and those without. Results 
showed a higher association of serum cholesterol and LDL in those with 
exudative maculopathy. It was also observed that TG,HDL and VLDL 
did not show any difference between the 2 groups. 
Results from the Singapore Malay Eye Study(SMES) 79 showed 
that LDL cholesterol is an independent risk factor for any type of 
retinopathy. 
SN-DREAMS Report Number 1380 was a population based cross 
sectional study conducted by Rajiv Raman et.al., at Sankara Nethralaya, 
it was found that out of the 1414 participants, one third had Diabetic 
macular edema and 6% of them had features suggestive of CSME. In 
their study they had compared risk factors associated with CSME and 
Non CSME separately and found that CSME patients had poor glycemic 
control, increased serum total cholesterol and microalbiminuria, whereas 
non CSME patients had high serum LDL, high non HDL cholesterol and 
increased cholesterol ratio. 
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The Atherosclerotic Risk in Communities Study (ARICS) 29 
was done to assess the prevalence of diabetic retinopathy and its 
associations with atherosclerosis and vascular risk factors. Out of the 
1600 patients enrolled 328(20.5%) had retinopathy, hard exudates were 
seen in 6.6%, proliferative diabetic retinopathy in 1.8% and 1.65 had 
macular edema. LDL cholesterol and plasma lipids were noted to be 
associated with retinal hard exudates. 
The Cardiovascular Health Study (CHS) 30was a population 
based cohort study done to see the relation between retinopathy and 
atherosclerosis and atherosclerotic risk factors. Their study showed that 
retinopathy was associated with higher systolic BP, increased levels of 
LDL and total cholesterols and presence of cardiovascular diseases. No 
association was found between retinopathy and HDL and triglycerides. 
The Beijing Eye Study (BES) 81,a population based study in  2945 
people, was aimed to determine the relation between various ocular 
disorders and dyslipidemia .They found that dyslipidemia was 
significantly associated with high IOP and atrophy of beta zone around 
the optic disc. 
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The ADVANCE Study 82 was done to find the association 
between HDL cholesterol and micro vascular diseases like retinopathy 
and nephropathy. In this study they found that HDL cholesterol had 
significant association in the development of renal micro vascular 
diseases but not in the retina. LDL cholesterol was found to be associated 
with the development of hard exudates and DME. 
The Hoorn Study 83 is a population based study to elaborate the 
factors for retinopathy in diabetic as well as non-diabetic patients. 
Positive association with retinopathy was noted with elevated BP, serum 
cholesterol, triglyceride and increased BMI. Also, increased BP,LDL 
cholesterol and plasma total cholesterol showed associations with retinal 
hard exudates.  
Study by Jyothi Idiculla et.al 84 of St. Johns Medical College, 
Bangalore, showed that those with increased levels of serum cholesterol 
and LDL had higher incidences of CSME. 
A study was conducted at government general hospital, Gundur, by 
Rajasekar et.al.,85 to find out the incidence of CSME in DR patients and 
to find out its associated risk factors. It was found that incidence of 
CSME increased with the duration of diabetes, level of glycemia control, 
lipid profiles, hypertension and nephropathy. They concluded that HbA1c 
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and high cholesterol levels were the most important factors or 
development of CSME.  
In an article by Sivaramareddy Kolli et,al. 86,100 diabetic patients 
were divided equally into those with maculopathy and those without. 
They observed that, those with maculopathy had a longer history of 
diabetes and had higher range of serum lipids including serum 
cholesterol, triglycerides, VLDL and LDL levels ,than those without. 
Rehab Benarous et.al 87 in their study found that, serum lipids 
were independently related to CSME, after adjusting for other common 
risk factors and also that  no such correlation was found with the presence 
and  severity of diabetic retinopathy, DME or thickness of the macula. 
Asesnsio Sanchez et.al. 88, in their study to find out the non 
ophthalmologic parameters as risk factors of CSME, found that HbA1c 
level was one of the main risk factors. It was observed that for each 1% 
increase in HbA1c,the risk of macular edema increased by double. Micro 
albuminuria also doubled the risk of edema of macula. LDL fraction of 
cholesterol was seen to increase the risk by a factor of 100%.Tobacco 
addiction also showed 100% association.  
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REVIEW OF LITERATURE CORRELATING HYPOLIPEDEMIC 
DRUGS  AND DR : 
Many lipid lowering drugs are under evaluation for their possible 
protective role in DR. 
A study by Gordon et.al. done in patients with diabetic 
retinopathy showed that statins (Pravastatin) is beneficial in improving 
DR and decreases hard exudate. In a recent study by Sen et.al., 
simvastatin was also found to be helpful in retarding the progression of 
DR. In another study atorvastatin was given for 4 months after 
application of laser treatment for CSME .Those patients who received 
atorvastatin showed prevention of edema extension into the central retina. 
The Collaborative Atorvastatin Diabetes Study (CARDS), 
showed that usage of 10mg of atorvastatin daily lead to a decrease in the 
laser therapy when compared with those not taking. But there was no 
effect on the progression  of retinopathy. 
The Action to Control Cardiovascular Risks In Diabetes( 
ACCORD),participants were divide into 2 groups, one receiving 
fenofibrate with simvastatin and other group receiving placebo with 
simvastatin. It was observed that the rate of progression of DR was lower 
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(6.2%) in those who took fenofibrates when compared to placebo 
(10.2%). 
In a study done on patients with  hyperlipoproteinemia, usage of 
etofibrate for 6 months showed a reduction of hard exudates. 
The Fenofibrates Intervention and Event Lowering in Diabetes 
(FIELD) study was a multinational trial done on those with type 2 
diabetes, where participants were divided into 2 groups, those receiving 
fenofibrate and those on placebo. Study showed a decreased requirement 
of first laser and also lowered the progression rate in those who received 
fibrate.  
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AIM & OBJECTIVES 
AIM :  
To correlate the levels of serum lipid and presence of clinically 
significant macular edema in diabetic retinopathy patients. 
OBJECTIVES: 
1) To study the serum lipid profile in patients with diabetic 
retinopathy. 
2) To compare the serum lipid profile of patients with and without 
clinically significant macular edema. 
3) To compare and analyze the present study with reference to other 
studies on serum lipid profile in diabetic retinopathy. 
4) To emphasize the importance of doing serum lipid profile as a 
routine investigation in patients with diabetic retinopathy and to 
initiate treatment for those appropriate. 
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MATERIALS AND METHODS 
STUDY GROUP: 
The study was conducted on patients with diabetic retinopathy 
visiting department of ophthalmology, Coimbatore Medical College 
Hospital, Coimbatore. 
PERIOD OF STUDY: 
The study was conducted for a period of one year from January 
2017 to December 2017. 
INCLUSION CRITERIA: 
Patients aged more than 40 years having type 2 diabetes mellitus 
with retinopathy, in euglycemic status during the time  of study, attending 
ophthalmology outpatient department and  are willing to participate in the 
study and have given consent to undergo blood tests for serum lipid levels 
and renal parameters, were included in the study. 
EXCLUSION CRITERIA: 
1) Patients with type 1 diabetes mellitus. 
2) Patients with any pre existing retinal manifestations of systemic 
diseases, other than DR. 
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3) Patients who have had treatment for diabetic retinopathy 
4) Patients on treatment for dyslipidemias. 
5) Patients with macular dystrophies and degenerations. 
6) Patients with ocular anomalies. 
7) Patients with ocular trauma. 
SAMPLE SIZE: 
200 patients divided in to two groups of 100 each. 
Group A: Patients with diabetic retinopathy with clinically significant 
macular edema. 
Group B: Patients with diabetic retinopathy without clinically significant 
macular edema. 
SELECTION OF STUDY SUBJECTS: 
Hundred consecutive patients each of Group A and Group B 
presenting to ophthalmology outpatient department and those referred 
from other departments with diabetic retinopathy fulfilling the inclusion 
criteria of the study were selected. 
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METHODS: 
Informed written consent was obtained from the selected patients 
and data collected using structured questionnaire which comprises socio-
demographic characteristics like age, gender, history of duration of 
diabetes mellitus, history of usage of insulin, duration of insulin usage, 
treatment history, presence of other systemic conditions like hypertension 
and renal disease. 
Anterior segment evaluation was done by slit lamp examination. 
After dilatation of the pupil with tropicamide and phenylephrine eye 
drops, fundus examination was done using direct ophthalmoscopy, 
indirect ophthalmoscopy and slit lamp bio microscopy with +90D lens. 
Appropriate fundus photographs and FFA were taken. Diabetic 
retinopathy was classified according to ETDRS classification. 
All patients were advised overnight fasting and blood samples were 
taken for estimation of fasting blood glucose, serum lipid levels, blood 
urea and serum creatinine. Systolic and Diastolic Blood pressures were 
measured in sitting posture. Those patients with higher fasting blood 
glucose values in initial recording were included in the study only after 
maintaining a euglycemic status for 1 month. 
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RESULTS AND OBSERVATIONS 
 
The data analysis was performed using statistical software package 
SPSS version 22.0.Both the descriptive and inferential statistics were 
used. The continuous variables were summarized as mean with standard 
deviation. The categorical variables were summarized as frequencies and 
proportions. The comparison of continuous variables were done using 
unpaired ‘t’ test and comparison of categorical variables were done using 
Chi square test or Fisher’s exact test depending on distribution. P value of 
less than 0.05 was considered significant. 
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Group A : Patients with clinically significant macular edema 
 
Group B : Patients without clinically significant macular edema 
 
  Table -1: Age Distribution of Cases 
 
       
 
Age groups  Group A  Group B 
 
(in years)        
 
 
No. 
 
Percentage No. 
 
Percentage      
 
       
 
40- 50 14  14 16  16 
 
        
 
51 -60  41  41 46  46 
 
        
 
61 – 70  34  34 32  32 
 
        
 
70-80  10  10 6  6 
 
        
 
>80  1  1 0  0 
 
Total  100  100 100  100 
 
      
 
Range  40 – 87 yrs 42 – 77 yrs 
 
Mean  60.07 yrs 58.78 yrs 
 
S.D  8.41 7.77 
 
      
 
P    0.701 Not Significant 
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Patients with CSME had mean age of 60.07 years and without CSME 58.78 
years 
 
Age was not found to be significantly associated with the presence of 
CSME.(p=0.701) 
 
Chart- 1:Age wise distribution 
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Table -2: Sex Distribution of Cases 
 
Sex  Group A  Group B 
       
 No.  Percentage No.  Percentage 
       
Male 57  57 50  50 
       
Female 43  43 50  50 
       
Total 100  100 100  100 
      
P   0.321 Not significant  
       
 
Males slightly predominated the group with CSME with 57% and both were 
equal in numbers in the non CSME group. 
 
Chart-2:Sex distribution 
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Table -3: Duration of DM 
 
Duration of DM  Group A  Group B 
 
(in years)       
 
No. 
 
Percentage No. 
 
Percentage     
 
       
 
Newly detected 
 
11  11 14  14 
 
       
 
Up to 5 years 2  2 17  17 
 
       
 
6 – 10 years 31  31 68  68 
 
       
 
11 – 15 years 41  41 1  1 
 
       
 
> 15 years 15  15 0  0 
 
       
 
Total 100  100 100  100 
 
       
 
P value (< 15 yrs.   0.0000 
Signific
ant   
 
to > 15yrs)       
 
       
 
 
 
41% of the patients with CSME had type 2 Diabetes Mellitus for duration 
ranging from 11-15 years whereas most of the patients without CSME had 
diabetes mellitus for a duration ranging from 6-10 years comprising 68% of the 
total. Duration of DM showed statistical significance 
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Chart-3:Duration of diabetes with CSME 
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Table -4: Insulin usage 
 
Insulin use   Group A  Group B 
        
  No.  Percentage No.  Percentage 
        
Yes  44  44 47  47 
        
No  56  56 53  53 
       
P    0.670  Not significant  
        
 
Among the patients with CSME, 44% were on insulin and 47% among the 
patients without CSME were on insulin. Insulin usage was not found to be 
significantly related to presence or absence of CSME. 
 
Chart-4:Insulin Usage 
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Table -5: Duration of insulin usage 
Duration Group A Group B 
No. % No. % 
< 10 yrs 87 87 100 100 
≥10yrs 13 13 0 0 
p 0.0000 Significant 
 
Duration of insulin usage for more than 10 years showed statistical 
significance to the development of CSME(p=0.0000) 
 
Chart-5:Duration of insulin usage 
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Table -6: Severity of Diabetic Retinopathy 
 
DIABETIC 
RETINOPATHY 
SEVERITY 
RIGHT EYE LEFT EYE 
A B A B 
No. % No. % No. % No. % 
No DR 2 2 17 17 4 4 20 20 
Very Mild NPDR 2 2 7 7 6 6 5 5 
Mild NPDR 7 7 36 36 12 12 45 45 
Moderate NPDR 38 38 29 29 45 45 23 23 
Severe NPDR 19 19 9 9 16 16 4 4 
Very Severe NPDR 14 14 0 0 7 7 0 0 
PDR 18 18 2 2 10 10 3 3 
 
Those with CSME and without CSME had most of the patients with Moderate 
NPDR. 
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Chart-6:Severity of diabetic retinopathy in right eye 
 
 
Chart-7:Severity of diabetic retinopathy in left eye 
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Table -7:Eye wise distribution: 
 
CSME 
  Right Eye     Left Eye    
             
 A  B  A  B  
             
No.  % No.  % No.  % No.  %  
             
Yes 69  69 0  0 62  62 0  0  
              
No 31  31 100  100 38  38 100  100  
              
 
 
Among the patients who had CSME, it was more common in right eye in our 
study than in left eye. 
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B. Relationship between Lipid Profile and incidence of CSME in 
patients with Diabetic Retinopathy 
 
Table -8: Total cholesterol and CSME 
 
Total Cholesterol 
 Group A  Group B 
      
No.  Percentage No.  Percentage 
       
Normal 
(≤200mg/dl) 
5  5 57  57 
       
Abnormal 
(>200mg/dl) 
95  95 43  43 
      
Range 140-518   112 – 412 
Mean  318.69  199.57 
SD  63.44  49.52 
     
P   0.0000 Significant 
       
 
 
Total cholesterol levels in patients of Group A ranged from 140 – 518 mg/dl 
with a mean of 318.69 mg / dl and Group B from 112 – 412 mg / dl with a 
mean of 199.57 mg / dl. Total cholesterol level was found to be statistically 
significant with a ‘p’ value of 0.0000. 
 
 
 
 
 
54 
 
Chart-8:Correlation of total cholesterol and CSME 
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Table -9: Triglyceride  and CSME 
 
TG 
 Group A  Group B 
      
No.  Percentage No.  Percentage 
       
Normal (≤150mg/dl) 5  5 34  34 
       
Abnormal 
(>150mg/dl) 
95  95 66  66 
       
Range  123 – 380  78 – 338 
Mean  257.07  164.89 
SD  57.54  40.62 
    
P  0.0000 Significant 
       
 
 
Patients without CSME  had a mean triglyceride levels of 164.89 mg/dl 
whereas patients with CSME had a higher triglyceride levels with a mean of 
257.07 mg / dl with the ‘p’ value of 0.0000, .Increased triglyceride levels were 
found to be significantly related to presence of CSME. 
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Chart -9: Correlation of Triglyceride and CSME 
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Table -10: HDL and CSME 
 
HDL 
 Group A  Group B 
      
No.  Percentage No.  Percentage 
      
Normal (> 40mg/dl) 15  15 85  85 
       
Abnormal 
(≤40mg/dl) 
85  85 15  15 
       
Range   12– 196  22 – 68 
Mean  35.49  49.13 
SD  25.03  8.93 
    
P  0.0000 Significant 
       
 
 
Patients with CSME had mean HDL-C levels of 35.49 mg/dl and those 
who did not have CSME had a mean of 49.13 mg / dl. Decreased serum 
HDL-C level was found to be significantly related to the presence of 
CSME. 
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Chart-10:Correlation of HDL cholesterol and CSME 
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Table -11: LDL and CSME 
 
LDL 
 Group A  Group B 
      
No.  Percentage No.  Percentage 
       
Normal (≤ 130mg/dl) 19  19 82  82 
       
Abnormal 
(>130mg/dl) 
81  81 18  18 
       
Range   26- 402  54 – 240 
Mean  195.48  107.73 
SD  69.80  37.45 
    
P  0.0000 Significant 
       
 
 
Patients with CSME had higher serum LDL-C levels with a mean of 195.48 mg 
/ dl compared to patients without CSME who had 107.73 mg% which was 
identified to be statistically significant.(0.0000) 
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Chart-11: Correlation of LDL cholesterol and CSME 
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Table -12: Blood Urea and CSME 
 
Blood Urea 
 Group A  Group B 
      
No.  Percentage No.  Percentage 
      
Normal (≤ 23mg/dl) 16  16 26  26 
       
Abnormal 
(>23mg/dl) 
84  84 74  74 
       
Range  21 – 38  17 – 70 
Mean  26.82  28.35 
SD  3.23  9.23 
    
P  0.1197 Not Significant 
       
 
 
Patients in group A and B  had  blood urea level on the higher side  and  
analysis showed no  statistical significance.(p=0.1197) 
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Chart-12: Correlation of Blood urea and CSME 
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Table -13: Serum Creatinine and CSME 
 
Serum Creatinine 
 Group A  Group B 
      
No.  Percentage No.  Percentage 
      
Normal (≤1.3mg/dl) 89  89 87  87 
       
Abnormal 
(>1.3mg/dl) 
11  11 13  13 
       
Range  0.7– 2.2  0.6 – 4.3 
Mean  1.003  1.089 
SD  0.33  0.66 
    
P  0.2470 Not Significant 
       
 
 
 
Patients with and without CSME were found to have decreased serum 
creatinine levels with mean value being 1.003 mg/dl and 1.089 mg/dl, 
respectively. It  showed no statistical significance.(p=0.2470) 
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Chart-13: Correlation of Serum creatinine and CSME 
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Table -14: Blood Pressure and CSME 
 
TGL 
Group A Group B 
‘p’     
Mean SD Mean SD 
    
Systolic 
BP(mm Hg) 
147.12 16.89 138.94 14.71 0.0003 
     Significant 
      
Diastolic 89.78 8.85 86.6 7.18 0.0058 
BP(mm Hg)     Significant 
      
 
 
Patients in both the groups had a mean SBP and DBP higher than normal 
values and showed statistical significance(P=0.0003 and P=0.0058 
respectively) 
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Chart-14: Correlation of Blood pressure and CSME 
 
 
  
0
20
40
60
80
100
120
140
160
SBP mmHg DBP mmHg
Group A Group B
 
 
67 
 
DISCUSSION 
 Diabetes Mellitus is an important health problem affecting the 
whole world.  Its impact is on the increase for the past many years, with 
326.5 million people suffering from it as per the 2017 records. Diabetic 
Macular Edema forms the leading cause of blindness among the patients 
with diabetic retinopathy. There have been many studies correlating the 
severity of diabetic retinopathy and the various risk factors, including 
level of serum lipids. Studies also have been reported regarding the 
efficiency of hypolipidemic drugs in decreasing the severity of 
retinopathy, maculopathy and vision loss. This study was done in our 
setting to observe how much the lipid level varies in those with CSME 
and those without in our region and to stress the importance of lipid 
lowering as a part of diabetic retinopathy management.   
Most of the results obtained in this study correlated with the 
available literature, both in the global scenario and the Indian set up. In 
the previously published studies, it was observed that the prevalence of 
diabetic retinopathy increases with duration of diabetes. In our study also 
DR severity increased with the number of years the patients has had DM.  
In our study, the most commonly seen stage of retinopathy was that of 
moderate NPDR, among those with CSME and without CSME. Among 
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the newly detected cases of diabetes most (75 %) had moderate NPDR 
and severe grades of retinopathy either in one or both eyes in both the 
groups. In the CSME group,92% had moderate NPDR and higher grades, 
whereas in the non CSME group, it was 50%.Out of the 21 newly 
detected cases,11 had CSME in either one or both eyes. This was 
observed to be in contrast with the Blue mountain study, where CSME 
was low (2%) in the newly diagnosed cases. This can be attributed to the 
fact that most patients especially from the rural areas get their diabetes 
detected after ophthalmoscopic examination when they present with 
complaints diminution of vision to ophthalmology OPD. 
Those with CSME had most number of cases in the 11-15 years 
duration group and those without CSME had maximum number of 
patients in the 6-10 years duration group. The significance of duration of 
diabetes is well evident from its correlation to CSME 
development.(p=0.0000).  
Analysis of the age distribution of patients showed that most 
people were in the 5th decade and that age and sex preponderance analysis  
did not show any statistical significance in the current study . Results of 
the important WESDR study also showed that the duration of  diabetes is 
more significant risk factor than the age of onset of diabetes.  
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Thirty three eyes, out of the 400 eyes studied showed  PDR,21 eyes 
showed very severe NPDR and 48 eyes had severe NPDR. Moderate 
NPDR accounted for the maximum (135 eyes).Mild and very mild NPDR 
was seen in 100 eyes and 20 eyes, respectively. Forty three eyes did not 
show any retinopathy changes. 
Among those with CSME, 84 eyes(42%) had severe  NPDR and 
higher grades of  retinopathy ,while those without CSME had severe 
forms of retinopathy in 18   eyes(9%).Most of the patients in both the 
groups had moderate NPDR.41.5% of eyes had moderate NPDR in the 
CSME group and26% of eyes had moderate NPDR in the non CSME 
group. 
In our study it was noted that not only the prevalence but also the 
severity of retinopathy also increases with the duration of diabetes. In the 
WESDR ,it was found that type 1 DM patients  with more than 5 years of 
diabetes had 13% prevalence of retinopathy and severe forms of 
retinopathy i.e., PDR was rarely found among these people. It was also 
seen that when the duration increased to 10-15 years, more than 90% had 
retinopathy and many(25%) showed proliferative changes. Type 2 DM 
patients were noted to have earlier onset of retinopathy changes and also 
higher grades of severity in earlier years itself. 
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In our study,91 patients were using insulin compared with 109 
people not using insulin (either newly detected or on OHAs).Those on 
insulin and having CSME was found to be 44 in number(48%%),while 
those on insulin and did  not develop CSME made 56 in number 
accounting for 51.3%. Only13% of people using insulin for 10 years or 
more had CSME and none were using for 10 or more years in the CSME 
group. The analysis of duration of insulin usage was found to be 
statistically significant in the occurrence of CSME (p=0.0000) 
It has been suggested that exogenous insulin may be a possible 
cause of atherosclerosis and retinopathy in people with type 2 diabetes. In 
the WESDR, there was no association between the amount or type of 
exogenous insulin used and the presence, severity, incidence or 
progression of retinopathy in the older onset group using insulin. 
Clinically Significant Macular Edema (CSME) was found to be 
more in the right eye. 
In the assessment of the study proper, it was observed that those 
with CSME had significantly increased levels of total cholesterol with an 
average value of 318.69mg/dL. Those without CMSE were found to have 
high values of total cholesterol but were less than that of those with 
CSME. The difference between the two groups was significant 
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statistically(p=0.0000).In a study done by Klein R et. al., it was observed 
that in type 2 diabetes group that did not use insulin, there was no 
relationship between total cholesterol and severity of hard exudates. 
In the ETDRS also those with elevated serum cholesterol had more 
chance of developing hard exudates. Study by Ucgun et.al., also had 
similar conclusion of positive association of serum cholesterol and 
exudative maculopathy. 
SN-DREAMS and  the Hoorn study had also concluded that total 
cholesterol level as significantly associated with development of CSME.  
In the Indian scenario also, separate studies done at  Sankara 
Nethralaya and by Jyothi Idiculla et.al., had observed the significant 
correlation of total cholesterol and CSME. 
Triglyceride levels in our study were observed to be higher in 
patients with CSME when compared with those without CSME. In the 
comparison of the 2 groups, statistical significance was 
present.(p=0.0000) .This as in contrast to the MESA study and study by 
Ucgun et.al., where the authors could not find any significant association 
between CSME and triglyceride levels. In a study  done on the North 
Indian population  by Sachdev N et.al., the author could find a significant 
association. 
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Lower levels of HDL-C was found to be associated with the 
development of CMSE in our study and was statistically 
significant.(p=0.0000).In the MESA study and study by Ucgun et.al., 
showed no significant association between HDL-C levels and presence of 
CSME. 
Higher levels of mean LDL-C (195.48mg/dl) were found in the 
group with CSME when compared with the non CSME 
group(107.73mg/dl) and was found to be statistically 
significant(p=0.0000).Similar findings were observed in the ARICS 
study, the CHS study ,the Hoorn study and the MESA study. In the 
Indian scenario also , the CURES study done in South of India and a 
study by Sachdevn et.al., from North India also showed similar results. In 
another study done in the South Indian population ,SN-DREAMS, no 
correlation was observed between the levels of LDL-C and CSME. 
In a study done at Macedonia by Golubovic-Arsovska, eventhough 
the levels of LDL-C was higher in those with CSME, there was no 
significant correlation observed. 
Analysis of the blood urea levels and serum creatinine levels  in 
our study population showed no significant correlation with CSME, with 
‘p’ values 0.1197 and 0.2470 respectively. This was similar  to study 
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published by Jew OM et.al., where they had found no significant 
association of blood urea and serum creatinine even though the values 
obtained in their study were high. A study by Rajasekhar P et.al., found a 
significant association of serum creatinine  with the development of  
CSME. 
Those with CSME had a mean Systolic blood pressure of  
147.12mm of Hg and a mean diastolic blood pressure of 89.78 mm of Hg. 
Those without CSME had a mean SBP of 138.94 mm of Hg and a mean 
DBP of 8.6 mm of Hg. There is a significant association between both 
SBP and DBP with the development of CSME(p=0.0003 and 0.0058) 
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SUMMARY 
The study “An analytical study correlating the significance of 
serum lipids in the development of clinically significant macular edema 
in patients with diabetic retinopathy” was a case control study with 200 
participants with diabetic retinopathy who had presented to the outpatient 
department of Coimbatore Medical College Hospital, Coimbatore.  
Patients were selected based on the inclusion criteria and exclusion 
criteria. A detailed history regarding the duration of diabetes, history and 
duration of insulin usage, duration of hypertension were taken. Patients 
were  examined using direct ophthalmoscope, slit lamp bio microscopy 
with + 90 D lens and with indirect ophthalmoscope.Colour fundus 
photographs were recorded and FFA was done. Blood investigations 
including fasting lipid profile, blood urea and serum creatinine were done 
for the selected subjects. Blood pressure was recorded. The above said 
variables were compared between those with and those without CSME. 
Findings from the study concluded that there was no significant 
difference in the age and sex distribution between the 2 groups. Duration 
of diabetes showed a significant association with the severity of diabetic 
retinopathy as well as the development of CSME. Insulin usage showed 
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no significance whereas and duration of insulin usage showed significant 
association in the development of CSME. 
Most of the patients with and without CSME were seen to be 
having moderate NPDR. In our study, it was observed that significantly 
higher levels of total cholesterol, triglycerides, LDL-C and significantly 
lower levels of HDL-C were found  among the patients with CSME when 
compared to those without CSME. 
Blood urea and serum creatinine were not found to be significantly 
associated with CSME. 
Both the systolic blood pressure and the diastolic blood pressure 
were found to be significantly higher among those with CSME when 
compared with those not having CSME.  
  
 
 
76 
 
CONCLUSION 
The present study gives a good evidence of a significant correlation 
between higher levels of total cholesterol, triglycerides and LDL-C and 
lower levels of HDL-C with the presence of clinically significant macular 
edema. Hypertension is also associated with CSME. 
Most of the diabetic patients are getting only oral hypoglycemics 
or insulin for the treatment of diabetes. The significance of lipid levels 
and the severity of hypertension in the development of exudative 
maculopathy is seen in the present study. Hence along with diabetes 
control drugs, lipid lowering drugs and anti-hypertensive drugs should be 
started for diabetic patients having dyslipidemia and hypertension. CSME 
is a vision threatening complication of diabetic retinopathy. Therefore, in 
order to prevent the loss of vision and to preserve or improve current 
visual acuity in those who have already developed CSME, adequate 
control of  hyperglycemia, hypertension and dyslipidemia must be 
ensured, in  every diabetic individual. 
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Fig:1 Proliferative diabetic retinopathy without CSME 
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Fig-2: Moderate NPDR with CSME with focal leakage 
 
Fig-3:Red free image of fig.2 
 
 
79 
 
 
Fig-4:Moderate NPDR with CSME with diffuse leakage 
 
Fig-5:Red free image of Fig.4 
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Fig-6: Moderate NPDR with CSME right eye 
 
Fig-7:Moderate NPDR with CSME left eye 
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Fig-8 : Fundus fluorescein angiography of fig.6 
 
Fig-9 : Fundus fluorescein angiography of fig.7 
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Fig 10 : OCT showing macular edema 
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PROFORMA  
Name:                                                                                 Date 
Age /sex:                                                                            OP No: 
History:                                                
Duration  of diabetes: 
Insulin usage:Y/N 
Duration of insulin usage: 
History of hypertension:Y/N 
Duration of hypertension:              
Any other relevant Past history: 
 
Clinical Examinaton:        
RE                
LE 
 
 1.Vision                                            
 2.Intraocular tension 
 3.Colour Vision 
 4.Fields 
 5.Slit Lamp examination with +90D lens: 
  i)Media- 
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  ii)Disc- 
 iii)Vessels- 
 iv)Macula- 
 
 
  
6.Fundus examination with indirect  
           Ophthalmoscope:  
        RE                                  LE 
 
          
 
 
 
 
 
 7.Fundus photograph: 
 8.Fundus fluorescein angiography 
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CONSENT FORM 
  
Hereby I volunteer and consent to participate in this study “AN 
ANALYTICAL STUDY CORRELATING THE SIGNIFICANCE 
OF SERUM LIPIDS IN THE DEVELOPMENT OF CLINICALLY 
SIGNIFICANT MACULAR EDEMA IN PATIENTS WITH  
DIABETIC RETINOPATHY”. I was fully explained about the nature 
of this study by the doctor; knowing which I 
Mr/Ms/Mrs.……………………. Fully consent to volunteer in this study. 
 
 
Date:       Signature of the volunteer 
Place: 
       Signature of the witness 
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CONSENT FORM 
 I, Dr. PRAYAGI KANDOTH am carrying out a study on the 
topic, “AN ANALYTICAL STUDY CORRELATING THE 
SIGNIFICANCE OF SERUM LIPIDS IN THE DEVELOPMENT 
OF CLINICALLY SIGNIFICANT MACULAR EDEMA IN 
PATIENTS WITH DIABETIC RETINOPATHY”. 
My research project guide is Dr.V.Thaialnayaki, M.S., 
My research project is being carried out in the Department of 
Ophthalmology, Coimbatore Medical College Hospital, Coimbatore. 
RESEARCH BEING DONE: 
AN ANALYTICAL STUDY CORRELATING THE SIGNIFICANCE 
OF SERUM LIPIDS IN THE DEVELOPMENT OF CLINICALLY 
SIGNIFICANT MACULAR EDEMA IN PATIENTS WITH  DIABETIC 
RETINOPATHY  
PURPOSE OF RESEARCH: 
 To find out the association between serum lipid levels and 
development of clinically significant macular edema in diabetic 
retinopathy patients. 
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PROCEDURE INVOLVED: 
 The presence or absence of clinically significant macular o 
edema was found out by slit lamp bio microscopy  with +90D lens and by 
indirect ophthalmoscopy. The levels of serum lipids were estimated by 
taking fasting blood samples. Blood urea, serum creatinine, systolic and 
diastolic blood pressures were also recorded.  
 You, Shri./Smt./Kum. __________________, aged________ years 
S/o/ W/o/D/o________________, residing at_______________________ 
___________________________________ are requested to be a 
participant in the research study titled “AN ANALYTICAL STUDY 
CORRELATING THE SIGNIFICANCE OF SERUM LIPIDS IN 
THE DEVELOPMENT OF CLINICALLY SIGNIFICANT 
MACULAR EDEMA IN PATIENTS WITH  DIABETIC 
RETINOPATHY” in Government Coimbatore Medical College, 
Coimbatore. You satisfy eligibility criteria as per the inclusion criteria. 
You can ask any questions or seek any clarifications on the study that you 
may have before agreeing to participate. 
DECLINE FROM PARTICIPATION 
 You are hereby made aware that participation in this study is 
purely voluntary and honorary and that you have the option and the right 
to decline from participation in the study. 
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PRIVACY AND CONFIDENTIALITY 
 You are hereby assured about your privacy. Privacy of subject will 
be respected and any information about you or provided by you during 
the study will be kept strictly confidential. 
AUTHORIZATION TO PUBLISH RESULTS 
 Results of the study may be published for scientific purposes 
and/or presented to scientific groups, however you will not be identified; 
neither will your privacy be breached. 
STATEMENT OF CONSENT 
 I, ________________________, do hereby volunteer and consent 
to participate in this study being conducted by Dr. PRAYAGI 
KANDOTH. I have read and understood the consent from/or it has been 
read and explained to me in my own language. The study has been fully 
explained to me, and whenever I ask questions at any time. 
 
Date:    Signature/Left Thumb Impression of the 
Volunteer     
 
Date:    Signature and Name of witness 
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xg;g[jy; gotk;  
 
bgah;  : 
taJ  :            ghypdk; : 
Kfthp : 
 
muR nfhit kUj;Jtf; fy;Y}hpapy; fz; kUj;Jtj; Jiwapy; 
gl;lnkw;gog;g[ gapYk; khztp kU.g;uahfp fz;nlhj; mth;fs; 
nkw;bfhs;Sk; "clk;gpy; cs;s bfhGg;g[r; rj;Jf;Fk;/ rh;f;fiu 
nehapdhy; Vw;gl;l fz; ghjpg;gpw;Fk;/ rk;ge;jk; cs;sjh" vd;W 
kUj;jth;fs; bra;a[k; fz; ghpnrhjidf;F ehd; KGkdJld; 
rk;kjpf;fpnwd;. Ma;tpd; bra;Kiw bjhlh;ghd midj;J 
tpgu';fisa[k; nfl;L vdJ re;njf';fisj; bjspt[gLj;jpf; 
bfhz;nld;. 
ehd; ,e;j Ma;tpy; vd;id ghpnrhjid bra;a KG kdJlDk;/ 
Ra rpe;jida[lDk; rk;kjpf;fpnwd;. 
vdJ neha; gw;wpa ,e;j Ma;tpy; v';fsJ midj;J tpgu';fSk; 
ghJfhf;fg;gLtJld; neha; gFjpapd; g[ifg;glk; kw;Wk; ,jd; Kot[fs; 
Ma;tpjHpy; btspaplg;gLtjpy; Ml;nrgid ,y;iy vd;gijj; 
bjhptpj;Jf; bfhs;fpnwd;. ve;j neuj;jpYk; ,e;j Ma]tpypUe]J ehd] 
tpyfpf] bfhs]s vdf]F chpik cz]L vd]gija[k]  
mwpntd]. 
 
,lk]-       nehahspapd]  ifbahg]gk] 
njjp- 
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KEY TO MASTER CHART 
1- Male 
2- Female 
DR- Diabetic Retinopathy 
Stages of diabetic retinopathy-0-No diabetic retinopathy 
                          1-Very Mild NPDR 
                          2-Mild NPDR 
                          3-Moderate NPDR 
                          4-Severe NPDR 
                          5-Very Severe NPDR 
                          6-PDR 
CSME- Clinically Significant Macular Edema 
RE- Right Eye 
LE- Left Eye 
Insulin usage-1-Yes 
                2-No 
SBP- Systolic Blood Pressure 
DBP- Diastolic Blood Pressure 
DM- Diabetes Mellitus 
HTN- Hypertension 
HDL-High Density Lipoprotein 
LDL-Low Density Lipoprotein 
Y-Yes 
N-No 
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MASTER CHART 
 
S. 
No 
Name 
Age 
(yrs) 
Sex 
Total 
cholesterol 
Triglyceride HDL LDL 
DR Stage 
RE 
DR stage 
LE 
CSME 
RE 
CSME 
LE 
SBP DBP 
Blood 
urea 
S Creatinine 
Insulin 
usage 
Duration 
of DM 
Duration of 
Insulin usage 
Duration 
of HTN 
1 Kalimuthu 54 1 256 234 20 120 2 3 N Y 130 80 30 1.2 1 10 8 8 
2 Muthu 64 1 265 253 26 281 4 2 Y N 150 90 26 0.7 1 15 10 10 
3 seethayammal 44 2 280 266 14 166 3 1 Y N 120 70 32 0.9 1 8 8 4 
4 Veerammal 53 2 270 253 40 84 3 0 Y N 130 90 29 0.8 1 15 12 17 
5 Pitchai 54 1 289 263 23 160 0 3 N Y 160 100 38 2 1 10 8 8 
6 Murugan 60 1 288 266 34 164 6 3 Y N 110 70 27 0.8 1 15 7 7 
7 Patiyammal 68 2 303 277 12 191 3 4 N Y 140 90 29 1 1 13 5 9 
8 Bakiyam 60 2 290 267 30 269 3 3 Y Y 148 84 23 0.8 2 11 0 8 
9 subathal 47 2 300 278 35 180 2 4 N Y 130 90 25 0.7 2 12 0 6 
10 Ramasamy 48 1 302 289 22 166 3 5 Y Y 150 92 26 1 1 15 12 7 
11 Damodaran 51 1 277 256 31 130 3 2 Y N 164 94 29 1.1 2 10 0 12 
12 Sundari 65 2 403 378 35 184 6 6 Y Y 190 110 34 1.9 2 10 0 0 
13 Gurusami 75 1 279 254 26 166 6 4 Y Y 120 80 22 0.7 2 0 0 8 
14 Madheena 53 2 290 245 41 140 3 1 Y N 160 90 28 0.9 1 12 5 8 
15 Thangammal 87 2 311 278 28 174 5 2 Y Y 164 90 30 1.7 1 14 5 10 
16 Perumal 60 1 356 289 30 221 6 4 Y Y 180 110 32 1.9 2 10 0 5 
17 Thangammal 73 2 374 312 35 194 6 6 Y Y 150 92 27 1 1 11 11 1 
18 Chellamal 56 2 288 267 30 171 3 1 Y N 120 80 23 0.7 2 0 0 0 
19 Arumugam 49 1 356 300 23 214 5 4 Y Y 160 90 27 1.1 1 15 13 15 
20 Arokiyasamy 60 1 287 254 20 199 3 2 N Y 170 100 28 1.3 1 12 7 9 
21 Nagendran 48 1 315 276 38 240 4 3 N Y 150 90 25 1.2 1 10 2 6 
22 chinnasamy 65 1 325 269 54 196 4 3 Y N 148 90 28 1 2 6 0 6 
23 Masilamani 58 2 315 296 36 248 4 3 Y Y 150 88 27 1.1 2 13 0 10 
24 Mani 61 1 289 245 35 154 3 2 Y N 148 78 24 0.7 2 18 0 15 
25 Palaniyammal 57 2 278 250 42 201 3 2 Y N 168 88 23 0.7 2 0 0 3 
26 Sundaram 68 1 290 234 26 140 3 0 Y N 140 90 24 1 1 12 2 7 
27 Ravisankar 65 1 303 276 19 402 6 2 Y N 110 72 22 0.7 1 13 1 2 
28 Kuppamal 52 2 346 243 19 122 6 2 Y N 180 100 21 0.9 2 15 0 17 
29 Kaliyammal 71 2 359 300 22 192 6 5 Y Y 120 84 34 1.6 2 14 0 2 
30 Karuppayammal 60 2 423 256 35 110 5 1 Y N 170 110 26 0.7 1 16 13 6 
31 Ahmed 57 1 345 267 39 140 4 3 Y Y 166 98 29 0.8 1 10 3 8 
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32 Manikandan 54 1 325 300 22 220 3 3 Y Y 150 96 26 1 1 14 13 10 
33 Vellamal 80 2 430 320 35 90 6 4 Y N 170 100 30 1.1 2 14 0 10 
34 Pandidurai 70 1 378 265 25 308 4 3 Y Y 148 96 25 0.9 2 10 0 5 
35 Durairaj 63 1 311 268 24 219 3 3 Y N 130 80 27 0.7 2 0 0 0 
36 Deivathal 62 2 287 235 28 193 2 3 N Y 140 88 24 1 2 10 0 8 
37 Subbaiya 55 1 411 345 36 130 6 6 Y Y 166 96 27 1.1 1 16 14 12 
38 Subbalakhmi 44 2 356 312 40 161 5 5 Y Y 170 100 30 1.8 1 18 12 16 
39 Theresa 66 2 356 298 24 143 4 2 Y N 160 100 28 0.9 2 16 0 10 
40 Ponnammal 60 2 243 199 30 196 3 1 N Y 164 90 29 1 1 12 4 15 
41 Kanagambal 40 2 296 248 27 148 2 3 Y N 168 90 28 0.7 2 13 0 8 
42 Manivannan 60 1 340 312 31 300 5 4 Y N 140 86 27 0.8 2 10 0 6 
43 Jankai 65 2 356 325 30 212 5 6 N Y 158 100 29 0.9 1 18 15 12 
44 Chellappa 50 1 290 210 28 196 1 3 N Y 158 88 29 1.1 1 10 3 9 
45 Palanisamy 54 1 314 287 44 88 3 3 N Y 150 90 25 0.7 2 14 0 8 
46 Karuppusamy 48 1 378 324 23 200 4 3 Y N 130 92 25 0.7 2 18 0 6 
47 Periyasamy 64 1 346 333 30 150 6 6 Y N 150 86 28 0.8 1 20 3 5 
48 Nesamalar 72 2 330 287 22 184 3 2 N Y 148 84 26 0.7 2 16 0 15 
49 kaliyammal 74 2 298 247 17 211 3 0 Y N 130 90 28 1 2 0 0 0 
50 Veeramani 60 1 379 335 21 194 6 5 Y Y 120 70 26 0.9 2 0 0 8 
51 Ragasamy 65 1 390 337 30 195 5 3 N Y 130 90 26 0.8 1 12 3 2 
52 Sreenivasan 58 1 288 234 32 187 4 3 N Y 156 96 24 1 2 10 0 8 
53 Aiyaavoo 61 1 309 278 28 115 3 3 Y Y 160 100 29 1.8 1 15 7 0 
54 Lakshmi 57 2 367 327 40 167 6 4 Y N 156 96 25 1.2 2 17 0 5 
55 Moideen 68 1 276 235 31 160 4 3 N Y 148 90 28 1.3 2 12 0 6 
56 Shanmughasundaram 65 1 343 312 35 223 3 3 Y Y 120 90 32 1.4 2 10 0 10 
57 Veerapandi 52 1 365 318 36 235 2 3 N Y 134 80 28 0.7 2 12 0 5 
58 Devammal 65 2 427 356 60 311 6 6 Y Y 120 90 23 0.7 2 18 0 8 
59 Thirumathal 58 2 387 335 56 324 5 5 N Y 130 90 26 0.8 2 10 0 9 
60 Radhamani 61 2 267 212 53 156 4 3 N Y 134 94 23 0.7 1 13 0 8 
61 Badrammal 57 2 317 267 29 212 3 3 N Y 146 90 22 1.1 2 15 0 4 
62 Kanganbal 68 2 341 300 42 254 2 3 N Y 140 90 22 1 2 10 0 12 
63 Badrasami 65 1 305 265 40 234 5 4 Y Y 168 70 34 1.7 1 17 4 12 
64 Kaliyappan 52 1 411 356 36 318 5 6 Y Y 140 92 24 0.9 1 10 8 10 
65 Chinnappasamy 60 1 267 200 25 217 1 3 N Y 148 92 28 1.1 2 0 0 7 
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66 Jameela 68 2 284 217 86 225 3 3 Y N 130 90 23 0.9 1 10 1 10 
67 Kathirvel 60 1 267 166 53 200 4 3 Y N 146 80 24 0.7 2 14 0 1 
68 Mayilsamy 47 1 348 243 111 287 6 6 Y N 160 92 30 1.2 2 15 0 6 
69 Arokyasamy 48 1 376 306 32 243 3 3 Y Y 154 94 32 1.1 1 12 0 8 
70 Kannamal 51 2 351 267 35 235 3 3 Y Y 156 92 26 0.7 2 10 10 8 
71 Ponnappan 65 1 349 278 25 342 4 3 Y N 150 90 25 0.7 2 14 0 5 
72 Chidambaram 75 1 448 380 31 338 3 3 Y Y 136 82 26 1.2 2 11 0 1 
73 Vellamal 48 2 329 254 36 245 4 3 Y Y 146 90 23 0.8 1 14 7 8 
74 Kuppusamy 65 1 297 219 33 244 4 3 Y N 164 100 24 0.8 1 12 5 12 
75 Jayaraj 58 1 414 214 26 300 6 6 N Y 150 80 23 0.8 1 19 15 12 
76 Radha 61 2 140 125 12 122 3 1 Y N 134 86 22 0.9 1 9 2 10 
77 Kamaraj 57 1 160 145 35 90 5 4 Y N 146 90 22 0.7 1 9 4 2 
78 Sivagami 68 2 418 183 26 287 3 5 N Y 118 72 21 0.7 2 5 0 0 
79 Eswari 65 2 288 193 36 196 4 3 N Y 170 100 34 2.2 2 0 0 5 
80 Mani 52 1 312 165 42 200 4 3 N Y 150 86 26 1 1 7 1 6 
81 Ramathal 71 2 289 175 29 214 4 3 Y Y 156 88 29 0.7 1 8 1 10 
82 Kamaraj 60 1 251 180 113 30 3 2 Y N 164 110 28 0.9 2 7 0 8 
83 Senthil 57 1 310 182 24 246 3 4 N Y 164 90 29 0.9 2 0 0 5 
84 Chinnammal 50 2 287 166 21 221 3 0 Y N 140 80 27 0.9 2 5 0 9 
85 Gunasekaran 54 1 385 264 36 268 5 4 Y N 150 96 32 1 2 9 0 7 
86 Narayanasamy 48 1 229 189 26 164 5 6 N Y 120 70 26 1.3 2 8 0 8 
87 Vellamal 64 2 430 320 31 117 5 3 Y Y 170 100 30 1.1 2 14 0 10 
88 Pandidurai 72 1 378 265 25 168 3 3 Y Y 148 96 25 0.9 2 10 0 5 
89 Durairaj 74 1 311 268 22 153 4 3 Y N 130 80 27 0.7 2 13 0 6 
90 Deivathal 60 2 287 235 19 121 3 3 N Y 140 88 24 1 2 10 0 8 
91 Kalimuthu 65 1 347 168 35 224 3 3 Y Y 130 92 25 0.7 2 0 0 6 
92 Chandrasekhar 58 1 233 168 22 179 2 3 N Y 150 86 28 0.8 1 20 18 5 
93 Muniyandi 61 1 288 195 143 26 0 4 N Y 148 84 26 0.7 2 16 0 15 
94 Venugopal 57 2 248 167 22 166 6 4 Y Y 130 90 28 1 2 12 0 1 
95 Pechiyammal 68 1 193 136 35 120 3 4 Y N 120 70 26 0.9 2 10 0 8 
96 Kandhasamy 65 2 329 263 196 110 3 3 Y N 130 90 26 0.8 1 12 9 2 
97 Dhanabakyiam 56 2 190 130 30 130 3 2 Y N 156 96 24 1 2 0 0 8 
98 Marathal 62 1 142 123 12 122 3 5 Y N 160 100 29 1.8 1 15 13 0 
99 Marappan 54 1 518 318 34 402 6 3 N Y 156 96 25 1.2 1 12 12 2 
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100 Senthinathan 67 1 307 267 25 243 3 4 Y Y 164 100 28 1 1 6 5 4 
101 Vetrivel 57 1 112 104 35 60 2 1 N N 130 86 26 0.8 1 8 5 7 
102 Karupayee 75 2 156 124 39 108 3 2 N N 124 80 18 0.6 1 7 5 6 
103 Chinnavel 55 1 148 118 45 82 0 2 N N 130 90 24 0.9 2 5 0 8 
104 Ganeshan 65 1 129 84 48 68 1 0 N N 120 80 36 0.9 2 9 0 10 
105 Saraswathi 54 2 143 93 45 74 2 2 N N 124 90 42 1.4 2 0 0 2 
106 Chellamal 70 2 246 170 40 112 4 3 N N 130 74 54 2.4 1 6 6 12 
107 Krishnan 60 1 400 212 43 156 3 2 N N 140 100 70 4.3 1 8 4 10 
108 Nallathambi 62 1 312 194 42 190 3 2 N N 170 106 63 2.6 1 6 4 7 
109 Kaliyammal 58 2 134 78 47 84 4 2 N N 140 90 29 1.1 1 8 8 8 
110 Masilamai 67 2 116 101 45 73 0 1 N N 120 80 32 1 2 8 0 58 
111 Fathima 45 2 188 112 41 121 4 2 N N 140 94 48 1.2 1 5 1 5 
112 Thirumalasamy 52 1 163 83 40 108 2 2 N N 134 80 33 0.8 1 7 2 11 
113 Venkatachalam 61 1 148 99 46 183 1 0 N N 130 80 24 0.8 1 9 4 5 
114 Kuppusamy 68 1 180 104 45 124 2 3 N N 126 76 19 0.9 2 4 0 4 
115 Sellamal 42 2 174 143 41 93 2 2 N N 120 80 29 0.8 1 7 3 6 
116 Kalavathi 58 2 116 97 40 54 2 0 N N 130 90 36 0.9 2 0 0 0 
117 Shanthi 47 2 412 338 42 123 3 2 N N 170 100 63 4.3 2 8 0 8 
118 Micheal John 61 1 158 153 44 74 4 3 N N 140 90 21 0.8 2 6 0 6 
119 Ramasamy 72 1 143 133 50 70 2 2 N N 130 80 24 0.8 2 8 0 6 
120 Muthammal 58 2 151 126 53 81 3 2 N N 134 84 32 0.7 1 7 2 7 
121 Jeyakodi 50 2 284 214 51 126 0 2 N N 140 100 43 2.1 2 5 0 5 
122 Vasantha 70 2 177 168 56 110 3 3 N N 120 80 36 0.9 1 7 3 7 
123 Sayeeda Beegum 49 2 164 143 59 103 2 3 N N 124 80 24 1.2 2 0 0 0 
124 Mahalingam 56 1 183 162 44 116 0 2 N N 130 86 25 1.1 2 4 0 1 
125 Nagarathinam 59 2 310 211 45 110 3 2 N N 160 100 51 4 1 6 6 5 
126 Kasi 65 1 180 165 48 101 3 4 N N 118 82 29 1.1 1 8 6 4 
127 Bagyalakshmi 62 2 137 113 41 56 0 2 N N 120 84 34 0.8 2 7 0 6 
128 Angammal 53 2 145 126 48 78 2 0 N N 130 86 19 0.9 2 8 0 8 
129 Adachiyammal 56 2 192 197 40 111 2 3 N N 120 80 21 1.1 1 7 5 7 
130 Devadas 77 1 142 156 38 83 4 3 N N 130 84 40 1.3 1 4 2 5 
131 Murugan 70 1 124 117 40 66 2 2 N N 124 80 33 0.9 1 7 1 4 
132 Dhanam 51 2 185 173 35 104 3 2 N N 134 86 24 0.8 2 0 0 5 
133 Rajammal 56 2 144 132 40 71 0 2 N N 110 70 28 1 2 7 0 8 
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134 Velathai 50 2 204 146 41 140 3 2 N N 114 78 17 0.7 2 8 0 10 
135 Mary 59 2 196 173 50 145 3 2 N N 120 82 23 0.9 2 5 0 9 
136 Gomathi 68 2 155 146 47 82 4 6 N N 124 82 36 1.2 2 9 0 7 
137 Selvaraj 63 1 183 167 45 114 0 2 N N 130 80 40 1.4 2 8 0 8 
138 Chinnakannu 56 1 147 138 48 190 4 2 N N 130 86 26 0.9 2 11 0 1 
139 Papamal 64 2 316 261 52 124 3 2 N N 140 88 18 0.7 2 10 0 8 
140 Pandidurai 48 1 182 165 54 102 2 0 N N 134 82 32 1 2 5 0 10 
141 Radha 55 2 156 148 57 84 3 0 N N 124 84 19 1 1 9 5 8 
142 Pitchai 53 1 214 193 51 86 0 2 N N 130 80 27 1.1 2 0 0 3 
143 Singaram 60 1 210 140 60 106 2 3 N N 144 90 28 1 2 0 0 0 
144 Sethulakshmi 64 22 190 170 67 102 2 0 N N 146 86 23 0.7 1 6 4 4 
145 Chidambaram 60 1 197 150 60 120 2 0 N N 134 70 21 0.8 1 8 6 12 
146 Palaniyappan 63 1 188 190 62 122 2 2 N N 154 88 26 0.8 1 7 7 6 
147 Muniyandi 59 1 176 200 56 194 4 3 N N 130 92 25 1 1 5 2 5 
148 Subbaiyah 53 1 210 205 53 60 3 2 N N 144 84 27 0.9 1 7 1 7 
149 Noorjahan 55 2 234 179 57 108 3 2 N N 146 88 27 0.8 1 8 1 8 
150 Jamal 48 1 196 248 47 82 4 6 N N 144 84 26 0.7 2 6 0 6 
151 Valliyammal 57 2 178 190 35 68 0 3 N N 166 90 23 0.7 2 7 0 10 
152 Nagammal 75 2 200 160 44 74 3 2 N N 134 90 25 0.9 1 6 4 5 
153 Thomas 55 1 203 158 64 201 2 2 N N 146 88 24 1 1 6 5 6 
154 Motchamary 65 2 236 163 55 240 2 0 N N 140 90 22 0.7 2 8 0 3 
155 Perumal 54 1 225 153 68 190 3 0 N N 136 84 22 0.8 2 9 0 8 
156 Susheela 70 2 218 210 47 84 0 2 N N 168 98 24 0.7 2 6 0 10 
157 Dhandapani 60 1 215 135 63 73 2 3 N N 160 90 27 1 1 6 7 12 
158 Palanathal 62 2 187 230 67 121 2 0 N N 148 80 27 0.7 2 0 0 1 
159 Kathirvel 58 1 212 167 42 108 0 2 N N 170 100 32 2 2 7 0 5 
160 Ponnamal 67 2 240 178 44 83 3 2 N N 130 80 26 0.8 1 7 4 3 
161 Esari 45 2 243 183 40 124 2 2 N N 144 90 26 0.8 1 5 5 5 
162 Karuppan 52 1 235 150 65 110 6 3 N N 146 86 23 1.1 1 8 1 7 
163 Alima 61 2 228 169 60 123 3 3 N N 160 100 29 1 2 0 0 2 
164 Sivagnanam 68 1 217 178 66 214 3 0 N N 154 88 23 1 1 7 2 17 
165 Anbu 42 2 191 185 54 132 3 4 N N 136 80 23 0.7 1 8 3 7 
166 Palani 58 1 189 164 46 122 1 0 N N 146 92 26 0.8 1 4 1 2 
167 Aruchamy 47 1 174 236 51 135 2 2 N N 154 94 28 0.9 1 7 1 17 
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168 Subban 61 1 208 176 54 167 3 0 N N 132 86 26 1.1 2 6 0 1 
169 Thangam 72 2 217 156 59 123 0 2 N N 110 74 29 1.7 1 8 4 5 
170 Raji 58 2 240 180 64 112 0 2 N N 120 80 23 0.9 2 0 0 3 
171 Muthu 50 1 223 167 66 111 2 3 N N 134 82 25 0.8 1 9 9 4 
172 Boominathan 70 1 256 165 22 83 1 0 N N 140 88 26 1 2 0 0 8 
173 Pushpa 49 2 190 188 56 66 2 2 N N 150 90 25 0.9 2 8 0 10 
174 Arumugham 56 1 187 190 47 104 2 0 N N 156 96 28 0.8 1 7 4 12 
175 Rangasamy 59 1 213 201 43 71 3 0 N N 110 70 27 1.8 2 4 0 0 
176 Panchavarnam 65 2 209 165 47 140 2 3 N N 158 98 24 2 2 6 0 5 
177 Selvakumar 62 1 177 150 45 145 1 3 N N 140 90 23 0.8 2 8 0 5 
178 Rajammal 53 2 179 156 54 82 6 6 N N 130 90 25 0.9 1 4 4 3 
179 Prema 56 2 200 185 42 114 2 1 N N 150 90 24 0.8 1 8 5 8 
180 Rajamani 77 2 211 164 47 90 2 3 N N 146 86 22 0.7 1 9 3 9 
181 Madhukumar 70 1 210 140 45 169 0 1 N N 130 80 27 1.1 2 0 0 7 
182 Marimuthu 51 1 190 170 40 102 3 1 N N 144 90 28 1 2 7 0 8 
183 Subramani 56 1 197 150 53 84 3 4 N N 146 86 23 0.7 2 9 0 8 
184 Ruckmani 50 2 196 248 57 146 0 2 N N 144 84 26 0.7 1 7 2 10 
185 Shanthi 59 2 178 190 64 82 1 0 N N 166 90 23 0.7 1 8 2 4 
186 Chandran 68 1 200 160 66 93 2 3 N N 134 90 25 0.9 1 5 1 1 
187 Mayangal 63 2 203 158 61 54 3 4 N N 146 88 24 1 2 7 0 5 
188 Philip 56 1 236 163 54 119 2 3 N N 140 90 22 0.7 1 8 6 6 
189 Kanappan 64 1 225 153 43 74 3 2 N N 136 84 22 0.8 1 8 8 6 
190 Ponraj 48 1 218 210 46 70 1 3 N N 168 98 24 0.7 2 0 0 8 
191 Murugesan 55 1 215 135 43 81 2 0 N N 160 90 27 1 1 9 5 7 
192 Kalavathi 53 2 199 138 42 90 0 2 N N 140 90 26 0.9 2 8 0 4 
193 Chinnamani 60 2 177 205 46 110 3 2 N N 144 84 24 0.7 1 4 1 7 
194 Anbmani 64 2 187 230 49 103 0 2 N N 148 80 27 0.7 2 7 0 8 
195 Balasubramaniyan 60 1 212 167 50 116 2 3 N N 170 100 32 2 2 0 0 5 
196 Rajamanikam 63 1 240 178 62 112 2 0 N N 130 80 26 0.8 2 8 0 6 
197 Palanisamy 59 1 243 183 40 101 2 3 N N 144 90 26 0.8 2 8 0 6 
198 Rangasamy 53 1 235 150 42 56 3 2 N N 146 86 23 1.1 2 5 0 7 
199 Muthammal 55 2 228 169 44 78 2 2 N N 160 100 29 1 2 4 0 10 
200 Rajalakshmi 48 2 217 178 46 89 2 3 N N 154 88 23 1 2 0 0 0 
 
